Virios Therapeutics initiated with a Buy rating, $1 price target at Maxim
PremiumThe FlyVirios Therapeutics initiated with a Buy rating, $1 price target at Maxim
2M ago
Virios Therapeutics initiated with a Buy at Maxim
Premium
The Fly
Virios Therapeutics initiated with a Buy at Maxim
2M ago
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
Premium
Press Releases
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
3M ago
Virios Therapeutics reports Q1 EPS (7c) vs. (8c) last year
PremiumThe FlyVirios Therapeutics reports Q1 EPS (7c) vs. (8c) last year
4M ago
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Premium
Press Releases
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
4M ago
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
Premium
Press Releases
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
5M ago
Virios Therapeutics announces director fee, management team salary cut
PremiumThe FlyVirios Therapeutics announces director fee, management team salary cut
6M ago
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
Premium
Press Releases
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
6M ago
Virios Therapeutics Enacts Salary Cuts and Grants Stock Options
Premium
Company Announcements
Virios Therapeutics Enacts Salary Cuts and Grants Stock Options
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100